hide
Free keywords:
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN-OLIGODENDROCYTE
GLYCOPROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS;
CENTRAL-NERVOUS-SYSTEM; T-CELL-RECEPTOR; BASIC-PROTEIN PEPTIDE;
ANTIGEN-PRESENTING CELLS; REDUCES RELAPSE RATE; CD8(+) T; B-CELLSExperimental autoimmune encephlalomyelitis (EAE); Spontaneous EAE
models; Humanized EAE models; Multiple sclerosis (MS); HLA-II transgenic
mice; Antigen-based immune-specific therapy;
Abstract:
Multiple sclerosis (MS), a demyelinating disease of the central nervous system (CNS), presents as a complex disease with variable clinical and pathological manifestations, involving different pathogenic pathways. Animal models, particularly experimental autoimmune encephalomyelitis (EAE), have been key to deciphering the pathophysiology of MS, although no single model can recapitulate the complexity and diversity of MS, or can, to date, integrate the diverse pathogenic pathways. Since the first EAE model was introduced decades ago, multiple classic (induced), spontaneous, and humanized EAE models have been developed, each recapitulating particular aspects of MS pathogenesis. The advances in technologies of genetic ablation and transgenesis in mice of C57BL/6J background and the development of myelinoligodendrocyte glycoprotein (MOG)-induced EAE in C57BL/6J mice yielded several spontaneous and humanized EAE models, and resulted in a plethora of EAE models in which the role of specific genes or cell populations could be precisely interrogated, towards modeling specific pathways of MS pathogenesis/regulation in MS. Collectively, the numerous studies on the different EAE models contributed immensely to our basic understanding of cellular and molecular pathways in MS pathogenesis as well as to the development of therapeutic agents: several drugs available today as disease modifying treatments were developed from direct studies on EAE models, and many others were tested or validated in EAE. In this review, we discuss the contribution of major classic, spontaneous, and humanized EAE models to our understanding of MS pathophysiology and to insights leading to devising current and future therapies for this disease. (C) 2014 Elsevier Ltd. All rights reserved.
